It's fair to say that Sarah-Jane Chilver-Stainer is a highachiever. When she spoke to Treasury & Risk earlierthis month, she had just completed a record-breaking dollar bondissue for GlaxoSmithKline, the London-based pharmaceutical andhealthcare company. The $5 billion issue, which attracted $15billion in demand, included three-, five- and 10-year notes withcoupons of 0.75%, 1.5% and 2.85%, respectively—the lowest couponsever achieved on U.S. dollar bonds sold by a UK company.

For Chilver-Stainer, the transaction was just the latest in aseries of accomplishments at GlaxoSmithKline (GSK), which had $44.2billion in 2011 revenue and employs more than 97,000 around theworld. GSK's group treasurer and senior vice president recently setup a new pension risk management team and took on responsibilityfor the company's insurance activities. She completed a majorreorganization of the treasury team at the beginning of the yearand recently established an in-house bank.

Aside from these projects, Chilver-Stainer points out theimportance of keeping the nuts and bolts of treasury on track, suchas managing the company's $23 billion debt portfolio and its $9.5billion investment portfolio. She joined SmithKline Beecham, one ofGSK's predecessor companies, in 1995 and held a number of treasuryroles before she was appointed to her current position in 2008.Today Chilver-Stainer manages a centralized treasury team coveringGSK's activities in more than 100 countries. Her areas ofresponsibility include corporate finance, the global treasuryconsultancy, cash management and the new pension team, as well asher insurance responsibilities.